

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant ID1540

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Medac GmbH (treosulfan) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Amyloidosis Research Consortium UK • Antony Nolan • Black Health Agency • Genetic Alliance UK • Metabolic Support UK • Muslim Council of Britain • PID UK • Sickle Cell Society • South Asian Health Foundation • Specialised Healthcare Alliance • UK Thalassaemia Society <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses & Counsellors • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Human Genetics • British Transplantation Society • ESPIRIT • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah’s Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (fludarabine, busulfan) • Actavis (fludarabine) • Aspen (busulfan, melphalan) • Baxter (cyclophosphamide) • Hospira UK (fludarabine) • Pierre Fabre (busulfan) • Sandoz (fludarabine, cyclophosphamide) • Teva (fludarabine)

Provisional matrix for the proposed technology appraisal of treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant ID1540

Issue date: January 2019

© National Institute for Health and Care Excellence 2019. All rights reserved.

Page 1 of 3

Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders • UK Genetic Testing Network • United Kingdom Primary Immunodeficiency Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS East Leicestershire and Rutland CCG • NHS England • NHS Newcastle Gateshead CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Cystic Fibrosis and Genetic Disorders Group • Cochrane Metabolic & Endocrine Disorders Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.